Global NGS-Based RNA-Sequencing Market
Global NGS-Based RNA-Sequencing Market

NGS-Based RNA-Sequencing Comprehensive Study by Type (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Application (Cancer Biomarkers, Cancer Heterogeneity and Drug Resistance, Cancer Immune Microenvironment, Others), Technology (SBS, SMRT, Nanopore), Verticals (Clinics, Laboratories, Pharmaceutical, Others) Players and Region - Global Market Outlook to 2027

NGS-Based RNA-Sequencing Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 202 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. by type (Sample Preparation, Platforms & Consumables, Services and Data Analysis) , by application (Cancer Biomarkers, Cancer Heterogeneity and Drug Resistance, Cancer Immune Microenvironment and Others) and major geographies.

What is NGS-Based RNA-Sequencing?
NGS-Based RNA-Sequencing is increasingly the method of choice for researchers studying the transcriptome. It offers some advantages over gene expression arrays. It is a sequencing technique that uses next-generation sequencing to reveal the presence and quantity of RNA in a biological sample at a given moment, analyzing the continuously changing cellular transcriptome. Increasing diseases like cancer and others is the major factors driving that market growth North America dominates the global NGS-Based RNA-Sequencing market.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledIllumina (United States), Thermo Fisher Scientific (United States), BGI Genomics (China), Agilent Technologies (United States), 10X Genomics (United States), QIAGEN (Germany), GENEWIZ (United States), MACROGEN (United States), Pacific Biosciences of California (United States) and Oxford Nanopore Technologies (United States)
CAGR%


The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this NGS-Based RNA-Sequencing market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Illumina (United States), Thermo Fisher Scientific (United States), BGI Genomics (China), Agilent Technologies (United States), 10X Genomics (United States), QIAGEN (Germany), GENEWIZ (United States), MACROGEN (United States), Pacific Biosciences of California (United States) and Oxford Nanopore Technologies (United States).

Market Overview:
In 2021, Illumina, Inc. has acquired GRAIL. The acquisition will boost access and adoption of the life-saving test worldwide. The transaction is driven by the belief that the life-saving test should be available to as many people as possible as quickly as possible.
The FDAs proposed framework also raises concerns as to whether it effectively protects consumer safety or threatens scientific discovery and innovation. As questions about regulation, statutory power, and legislation reform remain, the FDA and healthcare leaders must consider logistical and stakeholder challenges if they seek to transform clinical care with NGS technology.
Global NGS-Based RNA-Sequencing is a fragmented market due to the presence of various players. The players are focusing on investing more in Launching New Technologies. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Market Trend
Development in Portable Sequencing Technology and Rapid Advances in Genomic Technology
Restraints
  • High Cost Associated with the NGS-Based RNA-Sequencing

Opportunities
Increasing Applications of RNA-Sequencing in the Field of Cancer is creating Opportunities for the Market Growth

Key highlights of the Global NGS-Based RNA-Sequencing market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the NGS-Based RNA-Sequencing market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global NGS-Based RNA-Sequencing market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of NGS-Based RNA-Sequencing Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global NGS-Based RNA-Sequencing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in NGS-Based RNA-Sequencing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes NGS-Based RNA-Sequencing Regulatory Bodies, Potential Investors, New Entrants, Research and Development Institutes and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. Where the NGS-Based RNA-Sequencing industry is heading?
NGS-Based RNA-Sequencing Market is heading robustly to achieve new growth cycle.

2. Is NGS-Based RNA-Sequencing market is changing from growth to value?
The Concentration Rate of Global NGS-Based RNA-Sequencing market is dominated by Players and may generate healthy valuation by 2027.

3. Who are the key players profiled in the NGS-Based RNA-Sequencing Market?
Companies that are profiled in Global NGS-Based RNA-Sequencing Market are Illumina (United States), Thermo Fisher Scientific (United States), BGI Genomics (China), Agilent Technologies (United States), 10X Genomics (United States), QIAGEN (Germany), GENEWIZ (United States), MACROGEN (United States), Pacific Biosciences of California (United States) and Oxford Nanopore Technologies (United States) etc.
Report Objectives / Segmentation Covered
By Type
  • Sample Preparation
  • Platforms & Consumables
  • Services
  • Data Analysis
By Application
  • Cancer Biomarkers
  • Cancer Heterogeneity and Drug Resistance
  • Cancer Immune Microenvironment
  • Others
By Technology
  • SBS
  • SMRT
  • Nanopore

By Verticals
  • Clinics
  • Laboratories
  • Pharmaceutical
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Adoption by Laboratories to Study more deeply and assess Changes that may Indicate Disease
      • 3.2.2. Rapidly Developing Technologies in Next-Generation Sequencing
    • 3.3. Market Challenges
      • 3.3.1. Government Regulations on the NGS-Based RNA-Sequencing
    • 3.4. Market Trends
      • 3.4.1. Development in Portable Sequencing Technology
      • 3.4.2. Rapid Advances in Genomic Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global NGS-Based RNA-Sequencing, by Type, Application, Technology, Verticals and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global NGS-Based RNA-Sequencing (Value)
      • 5.2.1. Global NGS-Based RNA-Sequencing by: Type (Value)
        • 5.2.1.1. Sample Preparation
        • 5.2.1.2. Platforms & Consumables
        • 5.2.1.3. Services
        • 5.2.1.4. Data Analysis
      • 5.2.2. Global NGS-Based RNA-Sequencing by: Application (Value)
        • 5.2.2.1. Cancer Biomarkers
        • 5.2.2.2. Cancer Heterogeneity and Drug Resistance
        • 5.2.2.3. Cancer Immune Microenvironment
        • 5.2.2.4. Others
      • 5.2.3. Global NGS-Based RNA-Sequencing by: Technology (Value)
        • 5.2.3.1. SBS
        • 5.2.3.2. SMRT
        • 5.2.3.3. Nanopore
      • 5.2.4. Global NGS-Based RNA-Sequencing by: Verticals (Value)
        • 5.2.4.1. Clinics
        • 5.2.4.2. Laboratories
        • 5.2.4.3. Pharmaceutical
        • 5.2.4.4. Others
      • 5.2.5. Global NGS-Based RNA-Sequencing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global NGS-Based RNA-Sequencing (Price)
      • 5.3.1. Global NGS-Based RNA-Sequencing by: Type (Price)
  • 6. NGS-Based RNA-Sequencing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Illumina (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BGI Genomics (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent Technologies (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. 10X Genomics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. QIAGEN (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GENEWIZ (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MACROGEN (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pacific Biosciences of California (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Oxford Nanopore Technologies (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global NGS-Based RNA-Sequencing Sale, by Type, Application, Technology, Verticals and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global NGS-Based RNA-Sequencing (Value)
      • 7.2.1. Global NGS-Based RNA-Sequencing by: Type (Value)
        • 7.2.1.1. Sample Preparation
        • 7.2.1.2. Platforms & Consumables
        • 7.2.1.3. Services
        • 7.2.1.4. Data Analysis
      • 7.2.2. Global NGS-Based RNA-Sequencing by: Application (Value)
        • 7.2.2.1. Cancer Biomarkers
        • 7.2.2.2. Cancer Heterogeneity and Drug Resistance
        • 7.2.2.3. Cancer Immune Microenvironment
        • 7.2.2.4. Others
      • 7.2.3. Global NGS-Based RNA-Sequencing by: Technology (Value)
        • 7.2.3.1. SBS
        • 7.2.3.2. SMRT
        • 7.2.3.3. Nanopore
      • 7.2.4. Global NGS-Based RNA-Sequencing by: Verticals (Value)
        • 7.2.4.1. Clinics
        • 7.2.4.2. Laboratories
        • 7.2.4.3. Pharmaceutical
        • 7.2.4.4. Others
      • 7.2.5. Global NGS-Based RNA-Sequencing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global NGS-Based RNA-Sequencing (Price)
      • 7.3.1. Global NGS-Based RNA-Sequencing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. NGS-Based RNA-Sequencing: by Type(USD Million)
  • Table 2. NGS-Based RNA-Sequencing Sample Preparation , by Region USD Million (2016-2021)
  • Table 3. NGS-Based RNA-Sequencing Platforms & Consumables , by Region USD Million (2016-2021)
  • Table 4. NGS-Based RNA-Sequencing Services , by Region USD Million (2016-2021)
  • Table 5. NGS-Based RNA-Sequencing Data Analysis , by Region USD Million (2016-2021)
  • Table 6. NGS-Based RNA-Sequencing: by Application(USD Million)
  • Table 7. NGS-Based RNA-Sequencing Cancer Biomarkers , by Region USD Million (2016-2021)
  • Table 8. NGS-Based RNA-Sequencing Cancer Heterogeneity and Drug Resistance , by Region USD Million (2016-2021)
  • Table 9. NGS-Based RNA-Sequencing Cancer Immune Microenvironment , by Region USD Million (2016-2021)
  • Table 10. NGS-Based RNA-Sequencing Others , by Region USD Million (2016-2021)
  • Table 11. NGS-Based RNA-Sequencing: by Technology(USD Million)
  • Table 12. NGS-Based RNA-Sequencing SBS , by Region USD Million (2016-2021)
  • Table 13. NGS-Based RNA-Sequencing SMRT , by Region USD Million (2016-2021)
  • Table 14. NGS-Based RNA-Sequencing Nanopore , by Region USD Million (2016-2021)
  • Table 15. NGS-Based RNA-Sequencing: by Verticals(USD Million)
  • Table 16. NGS-Based RNA-Sequencing Clinics , by Region USD Million (2016-2021)
  • Table 17. NGS-Based RNA-Sequencing Laboratories , by Region USD Million (2016-2021)
  • Table 18. NGS-Based RNA-Sequencing Pharmaceutical , by Region USD Million (2016-2021)
  • Table 19. NGS-Based RNA-Sequencing Others , by Region USD Million (2016-2021)
  • Table 20. South America NGS-Based RNA-Sequencing, by Country USD Million (2016-2021)
  • Table 21. South America NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 22. South America NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 23. South America NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 24. South America NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 25. Brazil NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 26. Brazil NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 27. Brazil NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 28. Brazil NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 29. Argentina NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 30. Argentina NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 31. Argentina NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 32. Argentina NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 33. Rest of South America NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 34. Rest of South America NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 35. Rest of South America NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 36. Rest of South America NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 37. Asia Pacific NGS-Based RNA-Sequencing, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 41. Asia Pacific NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 42. China NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 43. China NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 44. China NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 45. China NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 46. Japan NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 47. Japan NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 48. Japan NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 49. Japan NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 50. India NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 51. India NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 52. India NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 53. India NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 54. South Korea NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 55. South Korea NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 56. South Korea NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 57. South Korea NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 58. Australia NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 59. Australia NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 60. Australia NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 61. Australia NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 66. Europe NGS-Based RNA-Sequencing, by Country USD Million (2016-2021)
  • Table 67. Europe NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 68. Europe NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 69. Europe NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 70. Europe NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 71. Germany NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 72. Germany NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 73. Germany NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 74. Germany NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 75. France NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 76. France NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 77. France NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 78. France NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 79. Italy NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 80. Italy NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 81. Italy NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 82. Italy NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 83. United Kingdom NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 84. United Kingdom NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 85. United Kingdom NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 86. United Kingdom NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 87. Netherlands NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 88. Netherlands NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 89. Netherlands NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 90. Netherlands NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 91. Rest of Europe NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 92. Rest of Europe NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 93. Rest of Europe NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 94. Rest of Europe NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 95. MEA NGS-Based RNA-Sequencing, by Country USD Million (2016-2021)
  • Table 96. MEA NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 97. MEA NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 98. MEA NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 99. MEA NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 100. Middle East NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 101. Middle East NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 102. Middle East NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 103. Middle East NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 104. Africa NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 105. Africa NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 106. Africa NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 107. Africa NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 108. North America NGS-Based RNA-Sequencing, by Country USD Million (2016-2021)
  • Table 109. North America NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 110. North America NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 111. North America NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 112. North America NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 113. United States NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 114. United States NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 115. United States NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 116. United States NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 117. Canada NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 118. Canada NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 119. Canada NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 120. Canada NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 121. Mexico NGS-Based RNA-Sequencing, by Type USD Million (2016-2021)
  • Table 122. Mexico NGS-Based RNA-Sequencing, by Application USD Million (2016-2021)
  • Table 123. Mexico NGS-Based RNA-Sequencing, by Technology USD Million (2016-2021)
  • Table 124. Mexico NGS-Based RNA-Sequencing, by Verticals USD Million (2016-2021)
  • Table 125. NGS-Based RNA-Sequencing: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. NGS-Based RNA-Sequencing: by Type(USD Million)
  • Table 137. NGS-Based RNA-Sequencing Sample Preparation , by Region USD Million (2022-2027)
  • Table 138. NGS-Based RNA-Sequencing Platforms & Consumables , by Region USD Million (2022-2027)
  • Table 139. NGS-Based RNA-Sequencing Services , by Region USD Million (2022-2027)
  • Table 140. NGS-Based RNA-Sequencing Data Analysis , by Region USD Million (2022-2027)
  • Table 141. NGS-Based RNA-Sequencing: by Application(USD Million)
  • Table 142. NGS-Based RNA-Sequencing Cancer Biomarkers , by Region USD Million (2022-2027)
  • Table 143. NGS-Based RNA-Sequencing Cancer Heterogeneity and Drug Resistance , by Region USD Million (2022-2027)
  • Table 144. NGS-Based RNA-Sequencing Cancer Immune Microenvironment , by Region USD Million (2022-2027)
  • Table 145. NGS-Based RNA-Sequencing Others , by Region USD Million (2022-2027)
  • Table 146. NGS-Based RNA-Sequencing: by Technology(USD Million)
  • Table 147. NGS-Based RNA-Sequencing SBS , by Region USD Million (2022-2027)
  • Table 148. NGS-Based RNA-Sequencing SMRT , by Region USD Million (2022-2027)
  • Table 149. NGS-Based RNA-Sequencing Nanopore , by Region USD Million (2022-2027)
  • Table 150. NGS-Based RNA-Sequencing: by Verticals(USD Million)
  • Table 151. NGS-Based RNA-Sequencing Clinics , by Region USD Million (2022-2027)
  • Table 152. NGS-Based RNA-Sequencing Laboratories , by Region USD Million (2022-2027)
  • Table 153. NGS-Based RNA-Sequencing Pharmaceutical , by Region USD Million (2022-2027)
  • Table 154. NGS-Based RNA-Sequencing Others , by Region USD Million (2022-2027)
  • Table 155. South America NGS-Based RNA-Sequencing, by Country USD Million (2022-2027)
  • Table 156. South America NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 157. South America NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 158. South America NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 159. South America NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 160. Brazil NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 161. Brazil NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 162. Brazil NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 163. Brazil NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 164. Argentina NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 165. Argentina NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 166. Argentina NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 167. Argentina NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 168. Rest of South America NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 169. Rest of South America NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 170. Rest of South America NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 171. Rest of South America NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 172. Asia Pacific NGS-Based RNA-Sequencing, by Country USD Million (2022-2027)
  • Table 173. Asia Pacific NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 174. Asia Pacific NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 175. Asia Pacific NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 176. Asia Pacific NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 177. China NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 178. China NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 179. China NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 180. China NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 181. Japan NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 182. Japan NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 183. Japan NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 184. Japan NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 185. India NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 186. India NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 187. India NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 188. India NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 189. South Korea NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 190. South Korea NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 191. South Korea NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 192. South Korea NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 193. Australia NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 194. Australia NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 195. Australia NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 196. Australia NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 201. Europe NGS-Based RNA-Sequencing, by Country USD Million (2022-2027)
  • Table 202. Europe NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 203. Europe NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 204. Europe NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 205. Europe NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 206. Germany NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 207. Germany NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 208. Germany NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 209. Germany NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 210. France NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 211. France NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 212. France NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 213. France NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 214. Italy NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 215. Italy NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 216. Italy NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 217. Italy NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 218. United Kingdom NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 219. United Kingdom NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 220. United Kingdom NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 221. United Kingdom NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 222. Netherlands NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 223. Netherlands NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 224. Netherlands NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 225. Netherlands NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 226. Rest of Europe NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 227. Rest of Europe NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 228. Rest of Europe NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 229. Rest of Europe NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 230. MEA NGS-Based RNA-Sequencing, by Country USD Million (2022-2027)
  • Table 231. MEA NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 232. MEA NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 233. MEA NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 234. MEA NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 235. Middle East NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 236. Middle East NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 237. Middle East NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 238. Middle East NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 239. Africa NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 240. Africa NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 241. Africa NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 242. Africa NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 243. North America NGS-Based RNA-Sequencing, by Country USD Million (2022-2027)
  • Table 244. North America NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 245. North America NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 246. North America NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 247. North America NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 248. United States NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 249. United States NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 250. United States NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 251. United States NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 252. Canada NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 253. Canada NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 254. Canada NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 255. Canada NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 256. Mexico NGS-Based RNA-Sequencing, by Type USD Million (2022-2027)
  • Table 257. Mexico NGS-Based RNA-Sequencing, by Application USD Million (2022-2027)
  • Table 258. Mexico NGS-Based RNA-Sequencing, by Technology USD Million (2022-2027)
  • Table 259. Mexico NGS-Based RNA-Sequencing, by Verticals USD Million (2022-2027)
  • Table 260. NGS-Based RNA-Sequencing: by Type(USD/Units)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global NGS-Based RNA-Sequencing: by Type USD Million (2016-2021)
  • Figure 5. Global NGS-Based RNA-Sequencing: by Application USD Million (2016-2021)
  • Figure 6. Global NGS-Based RNA-Sequencing: by Technology USD Million (2016-2021)
  • Figure 7. Global NGS-Based RNA-Sequencing: by Verticals USD Million (2016-2021)
  • Figure 8. South America NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 9. Asia Pacific NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 10. Europe NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 11. MEA NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 12. North America NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 13. Global NGS-Based RNA-Sequencing: by Type USD/Units (2016-2021)
  • Figure 14. Global NGS-Based RNA-Sequencing share by Players 2021 (%)
  • Figure 15. Global NGS-Based RNA-Sequencing share by Players (Top 3) 2021(%)
  • Figure 16. Global NGS-Based RNA-Sequencing share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Illumina (United States) Revenue, Net Income and Gross profit
  • Figure 19. Illumina (United States) Revenue: by Geography 2021
  • Figure 20. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 21. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 22. BGI Genomics (China) Revenue, Net Income and Gross profit
  • Figure 23. BGI Genomics (China) Revenue: by Geography 2021
  • Figure 24. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 25. Agilent Technologies (United States) Revenue: by Geography 2021
  • Figure 26. 10X Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 27. 10X Genomics (United States) Revenue: by Geography 2021
  • Figure 28. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 29. QIAGEN (Germany) Revenue: by Geography 2021
  • Figure 30. GENEWIZ (United States) Revenue, Net Income and Gross profit
  • Figure 31. GENEWIZ (United States) Revenue: by Geography 2021
  • Figure 32. MACROGEN (United States) Revenue, Net Income and Gross profit
  • Figure 33. MACROGEN (United States) Revenue: by Geography 2021
  • Figure 34. Pacific Biosciences of California (United States) Revenue, Net Income and Gross profit
  • Figure 35. Pacific Biosciences of California (United States) Revenue: by Geography 2021
  • Figure 36. Oxford Nanopore Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 37. Oxford Nanopore Technologies (United States) Revenue: by Geography 2021
  • Figure 38. Global NGS-Based RNA-Sequencing: by Type USD Million (2022-2027)
  • Figure 39. Global NGS-Based RNA-Sequencing: by Application USD Million (2022-2027)
  • Figure 40. Global NGS-Based RNA-Sequencing: by Technology USD Million (2022-2027)
  • Figure 41. Global NGS-Based RNA-Sequencing: by Verticals USD Million (2022-2027)
  • Figure 42. South America NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 43. Asia Pacific NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 44. Europe NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 45. MEA NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 46. North America NGS-Based RNA-Sequencing Share (%), by Country
  • Figure 47. Global NGS-Based RNA-Sequencing: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Illumina (United States)
  • Thermo Fisher Scientific (United States)
  • BGI Genomics (China)
  • Agilent Technologies (United States)
  • 10X Genomics (United States)
  • QIAGEN (Germany)
  • GENEWIZ (United States)
  • MACROGEN (United States)
  • Pacific Biosciences of California (United States)
  • Oxford Nanopore Technologies (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation